Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04284280Not ApplicableCompleted

Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants

Role: lead

NCT00759733Withdrawn

Evaluation Cardiac Function With Echo and BNP in Obstetrical Patients With/Without Cardiac Disease

Role: collaborator

NCT02967432Phase 2Completed

Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU

Role: lead

All 3 trials loaded